Brought to you by 
Reata licenses compounds, assay tech. from U. Texas
12 Nov 2019
Executive Summary
Reata Discovery, a company set up to commercialize drug candidates developed at Texas research institutions, has acquired the exclusive commercial rights from the University of Texas' Southwestern Medical Center and MD Anderson Cancer Center to several cancer compounds, plus Southwestern Medical's small-molecule drug discovery platform for cancer and neurodegenerative diseases.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Reata licenses compounds, assay tech. from U. Texas
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice